BGMD:OTC-BG Medicine Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.55M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


BG Medicine Inc (BGMD) Stock Analysis:
Based on the BG Medicine Inc stock forecasts from 0 analysts, the average analyst target price for BG Medicine Inc is not available over the next 12 months. BG Medicine Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BG Medicine Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, BG Medicine Inc’s stock price was USD 0.00. BG Medicine Inc’s stock price has changed by +0.00 % over the past week, +0.00 % over the past month and -99.50 % over the last year.

About

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galect ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOF EssilorLuxottica Société ano..

-5.98 (-2.88%)

USD87.77B 58.71 21.65
ESLOY EssilorLuxottica Société ano..

-0.35 (-0.35%)

USD87.77B 58.28 21.65
HOCPF HOYA Corporation

N/A

USD57.96B 44.95 0.23
HOCPY HOYA Corporation

-1.26 (-0.79%)

USD57.96B 43.61 0.23
SDMHF Sartorius Stedim Biotech S.A

N/A

USD53.25B 83.29 58.13
SUVPF Sartorius Aktiengesellschaft

-43.91 (-6.54%)

USD42.33B 202.83 42.54
SARTF Sartorius Aktiengesellschaft

-3.04 (-0.52%)

USD42.33B 174.42 42.54
RSMDF ResMed Inc

N/A

USD37.14B 29.24 33.11
CLPBF Coloplast A/S

-2.99 (-1.80%)

USD34.72B 47.19 4.97
CLPBY Coloplast A/S

+0.02 (+0.12%)

USD34.72B 47.96 4.97

ETFs Containing BGMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.86% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.86% 1% F 1% F
Trailing 12 Months  
Capital Gain -99.50% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.50% 3% F 1% F
Trailing 5 Years  
Capital Gain -99.89% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.89% 5% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain 23.15% 33% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.15% 31% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 113.59% 36% F 31% F
Risk Adjusted Return 20.38% 17% F 38% F
Market Capitalization 0.55M 20% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -0.15 84% B 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -902.64% 2% F 2% F
Return on Invested Capital -580.53% 3% F 2% F
Return on Assets -75.95% 12% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.66 33% F 26% F
Short Percent 10.14% 67% D+ 16% F
Beta 0.44 49% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.